Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 12, 2022

BUY
$2.14 - $5.23 $280,340 - $685,130
131,000 New
131,000 $360,000
Q1 2022

May 13, 2022

SELL
$5.1 - $13.06 $367,990 - $942,344
-72,155 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$8.41 - $16.71 $606,823 - $1.21 Million
72,155 New
72,155 $897,000

Others Institutions Holding GRPH

About Graphite Bio, Inc.


  • Ticker GRPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 58,211,200
  • Description
  • Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States. It offers GPH101, a gene-edited autologous hematopoietic stem cell product candidate to directly correct the mutation that causes sickle cell disease and restore normal adult hemoglobin expres...
More about GRPH
Track This Portfolio

Track Ergoteles LLC Portfolio

Follow Ergoteles LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ergoteles LLC with notifications on news.